Standigm ASK

At a glance

• Editor score
  5.6 / 10
• Pricing
  Pricing on request
• Best for
  Teams prioritizing disease-associated targets
• Target identification
  Yes
• Founded
  2015 · Seoul, Republic of Korea
• Facts checked
  4 Oct 2026

• Where it wins

  • Combines literature-derived and curated public evidence for target prioritization
  • Explores target evidence through pathways, disease–target paths, and gene expression
  • Can integrate in-house data and customer-specific database modifications

• Where it doesn't

  • Focused on target identification, not molecule design or drug repurposing
  • Cloud deployment may not suit teams requiring another deployment model
  • Access is sales-led rather than based on published self-service plans

Our verdict on Standigm ASK

Standigm ASK helps drug discovery researchers identify and prioritize novel targets for a selected disease or phenotype. It is aimed at teams that need evidence and biological context around target candidates, rather than software for designing molecules or repurposing existing drugs. Standigm describes the platform as AI-aided, combining curated public data and publication-derived information with knowledge-graph deep learning, natural-language processing, metabolic models, and network analysis. Its focus is target discovery, so it fits research teams whose immediate question is which disease-associated targets merit further investigation.

The product’s breadth is concentrated on target evidence. It supports genotype–phenotype prediction based on genome-scale metabolic models and random-walk modeling across protein-interaction networks and omics data. Researchers can interactively explore prioritization evidence, browse databases, and examine pathways, disease–target paths, and gene expression. Those views give users several routes to inspect predicted target relationships rather than treating a candidate list as the entire output. Customer-specific database modifications and integration of in-house data may also help teams bring internal research context into the workflow. ASK is available through the web and uses cloud deployment.

Access is sales-led: the vendor invites prospective users to contact it for a trial version, while its plans are not presented as public self-service tiers. That makes it sensible for teams prepared to discuss fit and access with Standigm, but less suited to buyers who need to evaluate published plan prices before engaging. Choose ASK when disease- or phenotype-driven target prioritization and evidence exploration are central needs, particularly when internal data could be relevant. Teams seeking molecule design or drug repurposing should look elsewhere, since those are outside ASK’s documented target-identification scope.

Your product? Our editors can test Standigm ASK in depth and publish a review, labelled as paid · from $99/mo →

Standigm ASK pricing

Standigm ASK fact sheet

Alternatives to Standigm ASK

• ABAmazon Bio DiscoveryA cloud workflow for designing, ranking, and testing antibody candidates.9.3
• PPharma.AIA broad discovery suite spanning target research, molecule design and clinical-trial prediction.8.8
• RRecursionA broad discovery suite for teams connecting computational models with lab experiments.8.7

See all Standigm ASK alternatives →

Featured on iTechGuides

Standigm ASK is listed in our AI Drug Discovery Software directory. Add the badge to your site — it links back to this page.

<a href="https://www.itechguides.com/products/standigm-ask/"><img src="https://www.itechguides.com/best/badge/standigm-ask.svg" alt="Featured on iTechGuides" width="230" height="46"></a>

Reviewed by iTechGuides Editors · Editorial team · Updated Oct 2026

Advertiser disclosure: iTechGuides is reader-supported. Vendors can pay for top positions in our rankings and for a place on other products' pages, and we may earn a commission when you click some links. How we rank.

Last updated 21 Oct 2026 · How we research and update